NCT05731518 - SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

February 28, 2026

Conditions

Small Cell Lung Cancer

Interventions

DRUG

SC0245

SC0245 Quaque Die(QD) administered with a 3-day on and 4-day off schedule in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.

DRUG

Irinotecan

Irinotecan 80mg/m\^2 via IV administered for every 4 weeks (fixed dosing) in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.

Trial Locations (1)

RECRUITING

Shanghai Chest Hospital, Shanghai